文献速递白血病淋巴瘤

通过过继转移Eμ-TCL1转基因小鼠脾细胞建立慢性淋巴细胞白血病小鼠模型

[Establishment of a chronic lymphocytic leukemia mouse model via adoptive transfer of Eμ-TCL1 transgenic splenocytes].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

研究将H11-Eμ-VH-TCL1-β-globin-PolyA基因敲入小鼠脾细胞腹腔注射至野生型C57BL/6J小鼠,建立慢性淋巴细胞白血病模型。移植后第9周,过继转移组出现脾大、肝大、外周血白细胞和B淋巴细胞增多,以及CD19+CD5+ B淋巴细胞在外周血、骨髓和脾中比例升高,脾、淋巴结、骨髓呈现慢性淋巴细胞白血病病理表现。

要点

  • 过继转移组脾重(0.92±0.16)g、肝重(2.11±0.56)g,均高于野生型组,P<0.05或P=0.006。
  • 过继转移组外周血白细胞(124.33±8.74)×10^9/L,高于野生型组(5.55±1.67)×10^9/L,P=0.002。
  • 过继转移组外周血、骨髓、脾CD19+CD5+ B淋巴细胞占比均高于野生型组,均P<0.05。

核心结论

  • 通过Eμ-TCL1转基因小鼠脾细胞过继转移成功建立了成型周期相对较短的慢性淋巴细胞白血病小鼠模型,可作为临床前模型用于慢性淋巴细胞白血病相关疾病研究。

研究设计与样本

  • 研究使用无特定病原体级C57BL/6J野生型小鼠和经CRISPR/Cas9技术构建、PCR鉴定基因型的H11-Eμ-VH-TCL1-β-globin-PolyA基因敲入小鼠。
  • 实验动物随机分为过继转移组和野生型对照组,每组10只;过继转移组经腹腔注射基因敲入小鼠脾细胞。
  • 移植后第9周以颈椎脱臼处死小鼠,通过病理学表现、外周血白细胞变化和免疫表型验证模型。

主要发现

  • 过继转移组脾重量(0.92±0.16)g高于野生型组(0.06±0.01)g(P<0.05),肝重量(2.11±0.56)g高于野生型组(1.42±0.13)g(P=0.006)。
  • 过继转移组外周血白细胞(124.33±8.74)×10^9/L高于野生型组(5.55±1.67)×10^9/L(P=0.002)。
  • 过继转移组外周血B淋巴细胞百分比(69.13±6.88)%高于野生型组(39.78±5.94)%(P<0.05)。
  • 过继转移组外周血、骨髓、脾中CD19+CD5+ B淋巴细胞占淋巴细胞百分比分别为(61.37±9.92)%、(28.61±7.08)%、(86.03±5.78)%,均高于野生型组的(4.51±1.32)%、(5.58±1.46)%、(14.33±3.20)%(均P<0.05)。
  • 过继转移组脾、淋巴结、骨髓出现慢性淋巴细胞白血病病理表现,肝、肺、肾组织有明显淋巴细胞浸润;瘤细胞CD43、CD200阳性,CD20、CD22、CD79b表达低于野生型B细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To generate a chronic lymphocytic leukemia (CLL) mouse model with intact immune competence and short latency by adoptively transferring (AT) splenocytes from immunoglobulin heavy-chain enhancer-driven T-cell leukemia/lymphoma 1 (Eμ-TCL1) transgenic donors into wild-type (WT) recipients. Methods: Specific pathogen-free C57BL/6J WT mice and H11-Eμ-VH-TCL1-β-globin-PolyA knock-in mice were utilized. The H11-Eμ-VH-TCL1-β-globin-PolyA knock-in mice were generated using CRISPR/Cas9 technology, and their genotypes were confirmed by PCR. Experimental animals were randomly divided into an adoptive transfer (AT) group and a WT control group (n=10 per group). Mice in the AT group received an intraperitoneal injection of splenocytes from H11-Eμ-VH-TCL1-β-globin-PolyA knock-in mice. The weight and general condition of the mice were monitored. Mice were euthanized by cervical dislocation at 9 weeks post-transplantation. The CLL model was validated using key indicators, including pathological manifestations, changes in peripheral blood leukocyte counts, and immunophenotype. Results: AT group mice exhibited significantly increased spleen weight [ (0.92±0.16) g vs (0.06±0.01) g in WT group, P<0.05] and liver weight [ (2.11±0.56) g vs (1.42±0.13) g in WT group, P=0.006], indicative of marked splenomegaly and hepatomegaly. The peripheral blood leukocyte count was significantly higher in the AT group [ (124.33±8.74) ×10(9)/L] compared to the WT group [ (5.55±1.67) ×10(9)/L] (P=0.002). Similarly, the percentage of peripheral blood B lymphocytes was markedly increased in the AT group versus the WT group [ (69.13±6.88) % vs (39.78±5.94) %, P<0.05]. Histopathological examination revealed CLL manifestations in the spleen, lymph nodes, and bone marrow of AT group mice, with significant lymphocytic infiltration observed in the liver, lung, and kidney tissues. Flow cytometry analysis showed that the percentages of CD19(+)CD5(+) B lymphocytes among total lymphocytes in peripheral blood, bone marrow, and spleen of the AT group were (61.37±9.92) %, (28.61± 7.08) %, and (86.03±5.78) %, respectively. These were significantly higher (all P<0.05) than in the WT group [ (4.51±1.32) %, (5.58±1.46) %, and (14.33±3.20) %]. Furthermore, these CLL-like cells in the AT group were positive for CD43 and CD200, but showed lower expression of CD20, CD22, and CD79b compared to WT B cells. Conclusion: Adoptive transfer of splenocytes from Eμ-TCL1 transgenic mice successfully established a CLL mouse model with a relatively short latency period. This model represents a valuable preclinical tool for investigating CLL and related pathologies. 目的: 利用免疫球蛋白重链增强子调控的T细胞白血病/淋巴瘤1(Eμ-TCL1)转基因小鼠脾细胞过继性转移(AT)至野生型(WT)小鼠体内,建立一种具有自身免疫功能、成模周期较短的慢性淋巴细胞白血病(CLL)小鼠模型。 方法: 实验使用了无特定病原体(SPF)级健康的C57BL/6J WT小鼠和H11-Eμ-VH-TCL1-β-globin-PolyA基因敲入小鼠。通过CRISPR/Cas9技术构建了H11-Eμ-VH-TCL1-β-globin-PolyA基因敲入小鼠,并采用PCR方法鉴定小鼠的基因型。实验动物被随机分为AT组和WT组,每组10只,AT组为H11-Eμ-VH-TCL1-β-globin-PolyA基因敲入小鼠脾细胞腹腔注射至体内的WT小鼠。监测小鼠的体重和一般情况,并在移植后第9周进行颈椎脱臼处死。通过病理学表现、外周血白细胞变化和免疫表型等关键指标对CLL小鼠模型进行疾病验证。 结果: AT组脾重量为(0.92±0.16)g、肝重量为(2.11±0.56)g;WT组脾重量为(0.06±0.01)g、肝重量为(1.42±0.13)g,AT组出现明显的肝(P=0.006)、脾(P<0.05)肿大。AT组外周血白细胞数量较WT组明显增多[(124.33±8.74)×10(9)/L对(5.55±1.67)×10(9)/L,P=0.002];AT组外周血B淋巴细胞百分比较WT组增多[(69.13±6.88)%对(39.78±5.94)%,P<0.05]。病理组织学检查发现AT组小鼠的脾、淋巴结、骨髓出现CLL病理表现,肝、肺、肾组织均有明显淋巴细胞浸润。流式细胞术检测结果示AT组CD19(+)CD5(+) B淋巴细胞占淋巴细胞百分比在外周血、骨髓和脾中分别为(61.37±9.92)%、(28.61±7.08)%、(86.03±5.78)%;WT组CD19(+)CD5(+) B淋巴细胞占淋巴细胞百分比在外周血、骨髓和脾中分别为(4.51±1.32)%、(5.58±1.46)%、(14.33±3.2)%;AT组外周血、骨髓、脾中CD19(+)CD5(+) B淋巴细胞占比较WT组增多,差异均具有统计学意义(均P<0.05),且CD43、CD200表达阳性,但CD20、CD22、CD79b的表达低于WT组。 结论: 通过Eμ-TCL1转基因小鼠脾细胞AT,成功建立了成型周期相对较短的CLL小鼠模型,其可作为一种理想的临床前模型用于CLL相关疾病研究。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang MX, Guo S, Nadiya A, et al. [Establishment of a chronic lymphocytic leukemia mouse model via adoptive transfer of Eμ-TCL1 transgenic splenocytes]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40623904. doi:10.3760/cma.j.cn121090-20241120-00461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。